Scientific article

Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome

Published inDiabetes, obesity & metabolism, vol. 11, no. 5, p. 445-454
Publication date2009

Changes in diagnostic criteria have impacted on the definition of the metabolic syndrome. The central aetiological importance of insulin resistance has lessened, while the role of other cardiovascular risk factors has progressively increased. Inflammatory mediators have also been identified as crucial targets for more selective therapies in metabolic syndrome. Among several pro-inflammatory factors, adiponectin has been shown to be associated with reduced cardiovascular risk in metabolic syndrome patients. Here, we review new therapeutic approaches, which could potentially increase adiponectin levels in metabolic syndrome.

  • Adiponectin/*metabolism
  • Angiotensin II Type 1 Receptor Blockers/pharmacology
  • Angiotensin-Converting Enzyme Inhibitors/pharmacology
  • Animals
  • Cardiovascular Diseases/complications/prevention & control
  • Clofibric Acid/pharmacology
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology
  • Insulin Resistance
  • Metabolic Syndrome X/complications/*drug therapy
  • Mice
  • Peroxisome Proliferator-Activated Receptors/agonists
  • Receptors, Cannabinoid/antagonists & inhibitors
  • Risk Factors
Citation (ISO format)
MONTECUCCO, Fabrizio, MACH, François. Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome. In: Diabetes, obesity & metabolism, 2009, vol. 11, n° 5, p. 445–454. doi: 10.1111/j.1463-1326.2008.00986.x
Main files (1)
ISSN of the journal1462-8902

Technical informations

Creation04/23/2012 1:24:28 PM
First validation04/23/2012 1:24:28 PM
Update time03/14/2023 5:26:18 PM
Status update03/14/2023 5:26:18 PM
Last indexation02/12/2024 8:02:04 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack